Vanderbilt Center for Neuroscience Drug Discovery

October 22, 2020

Lindsley to direct Center for Neuroscience Drug Discovery

Craig Lindsley, PhD, the William K. Warren Jr. Chair in Medicine and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery (WCNDD), effective Dec. 1. Lindsley assumes the director position from Jeffrey Conn, PhD, Lee. E. Limbird Chair in Pharmacology and professor of Pharmacology.

By VUMC News and Communications
Max Joffe, PhD, left, P. Jeffrey Conn, PhD, and colleagues are studying a new class of antidepressants that may relieve symptoms more rapidly and with fewer side effects.
November 21, 2019

Study explores potential new class of antidepressants

Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications.

By Bill Snyder
January 24, 2019

American Chemical Society honors Lindsley’s research

The year is starting off with a bang for Craig Lindsley, PhD, director of medicinal chemistry in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD).

By Bill Snyder
December 20, 2018

Lindsley named fellow of National Academy of Inventors

Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the National Academy of Inventors (NAI).

By Bill Snyder
November 15, 2018

Four researchers receive Young Investigator Grants

Four Vanderbilt University researchers are among 200 recipients of this year’s Young Investigator Grants awarded by the Brain & Behavior Research Foundation to support “innovative ideas for groundbreaking neurobiological research.”

By Bill Snyder
September 27, 2018

Innovative strategies crucial in opioid epidemic response

Reining in the nation’s opioid epidemic will require diverse and innovative strategies ranging from drug discovery to “policy translation,” according to speakers at a recent Vanderbilt Faculty Cutting-edge Discovery Lecture.

By Bill Snyder
February 1, 2018

AAAS, chemistry society honor Lindsley’s research contributions

Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the Royal Society of Chemistry and elected chair-elect of the Section of Pharmaceutical Sciences of the American Association for the Advancement of Science (AAAS).
By Bill Snyder
January 18, 2018

Investigators eye new target for treating movement disorders

Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.
By Bill Snyder
December 7, 2017

Lindsley honored by Pharmaceutical Society of Japan

Craig Lindsley, PhD, the William K. Warren Jr. Professor of Medicine at Vanderbilt, is the 2018 recipient of the Sato Memorial International Award of the Pharmaceutical Society of Japan.
By Bill Snyder
October 12, 2017

Award honors Conn’s mental health research contributions

P. Jeffrey Conn, Ph.D., founding director of the Vanderbilt Center for Neuroscience Drug Discovery, has won a 2017 Research & Hope Award from the Pharmaceutical Research and Manufacturers of America (PhRMA) for outstanding research in the area of mental health.
By Bill Snyder
September 21, 2017

University of Kansas honors Lindsley’s pharmacology research

Craig Lindsley, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been honored by the University of Kansas with the 2018 Edward E. Smissman Lectureship for his outstanding contributions to the fields of medicinal chemistry and molecular pharmacology.
By Bill Snyder
August 24, 2017

Drug discovery efforts may lead to new Rett syndrome treatments

Vanderbilt University research-ers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit.
By Bill Snyder
December 27, 2016

Investigational new drug for Alzheimer’s scheduled for first study in humans

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
By Craig Boerner
1 2 3